ClariTrial | Search Clinical Trials

Explore/autoimmune immunology

Status

Phase

Pre-filtered to show active, later-stage trials with the strongest clinical signal.

41 results for “autoimmune immunology” · Recruiting · Phase 3 · Phase 2

Page 1 of 3

Recruiting

A Clinical Trial to Investigate 18F-AzaFol in the Diagnosis of Large Vessel Vasculitis

Phase 2Giant Cell Arteritis

AzaFolFDG

Insel Gruppe AG, University Hospital Bern70 participants1 site · SwitzerlandCompletes May 2029

Compare CT.gov Full analysis →

Recruiting

A Clinical Study of CD19 Universal CAR-γδT Cells in Active Systemic Lupus Erythematosus

Phase 1Phase 2Systemic Lupus Erythematosus

CD19 Universal CAR-γδ T Cells

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology15 participants1 site · ChinaCompletes Dec 2025

Compare CT.gov Full analysis →

Recruiting

Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty

Phase 2Rheumatic Disease

MethotrexateSulfasalazineHydroxychloroquine+24 more

NYU Langone Health80 participants1 site · United StatesCompletes Jan 2028

Compare CT.gov Full analysis →

Recruiting

Immunosuppression and COVID-19 Boosters

Phase 3COVID-19

diphtheria and tetanus toxoids (adsorbed) vaccineCOVID-19 vaccine

Kirby Institute320 participants5 sites · AustraliaCompletes Dec 2026

Compare CT.gov Full analysis →

Recruiting

Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia Areata

Phase 2Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (Apeced)Alopecia Areata

Ruxolitinib

National Institute of Allergy and Infectious Diseases (NIAID)70 participants1 site · United StatesCompletes Dec 2027

Compare CT.gov Full analysis →

Recruiting

Randomized Stepped Wedge Study of Emapalumab in APECED Enteritis

Phase 2Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy Enteritis

Emapalumab

National Institute of Allergy and Infectious Diseases (NIAID)30 participants1 site · United StatesCompletes Mar 2031

Compare CT.gov Full analysis →

Recruiting

A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)

Phase 3Systematic Lupus ErythematosusCutaneous Lupus Erythematosus

EnpatoranPlaceboStandard of care (SoC)

EMD Serono Research & Development Institute, Inc.202 participants57 sites · United States, Australia, BrazilCompletes May 2029

Compare CT.gov Full analysis →

Recruiting

MB-CART19.1 in Refractory SLE

Phase 1Phase 2SLE - Systemic Lupus Erythematosus

MB-CART19.1

Miltenyi Biomedicine GmbH29 participants3 sites · GermanyCompletes Sep 2027

Compare CT.gov Full analysis →

Recruiting

STep-up and Step-down Therapeutic Strategies in Childhood ARthritiS

Phase 3Oligoarthritis, JuvenilePolyarthritis, Juvenile, Rheumatoid Factor Negative

EtanerceptMethotrexateIntra-articular corticosteroid injections

Istituto Giannina Gaslini260 participants1 site · ItalyCompletes Feb 2025

Compare CT.gov Full analysis →

Recruiting

Efficacy and Safety of CAR-T Cells Therapy for Chronic or Refractory Primary Immune Thrombocytopenia (ITP)

Phase 1Phase 2ITP - Immune Thrombocytopenia

CAR-T cells

920th Hospital of Joint Logistics Support Force of People's Liberation Army of China10 participants1 site · ChinaCompletes Jan 2026

Compare CT.gov Full analysis →

Recruiting

Ublituximab in Autoantibody Positive Immune Mediated Necrotizing Myopathy

Phase 2Autoimmune Disorders

UblituximabPlacebo for Ublituximab

National Institute of Allergy and Infectious Diseases (NIAID)30 participants8 sites · United StatesCompletes Aug 2028

Compare CT.gov Full analysis →

Recruiting

VIBRANT: VIB4920 for Active Lupus Nephritis

Phase 2Lupus Nephritis

VIB4920Placebo for VIB4920

National Institute of Allergy and Infectious Diseases (NIAID)74 participants17 sites · United StatesCompletes Jun 2028

Compare CT.gov Full analysis →

Recruiting

Autologous Gene Therapy for Artemis-Deficient SCID

Phase 1Phase 2Severe Combined Immunodeficiency

AProArt-CD34CliniMACS® CD34 Reagent System cell sorter deviceBusulfan

University of California, San Francisco24 participants1 site · United StatesCompletes Jun 2038

Compare CT.gov Full analysis →

Recruiting

Efficacy and Safety of Telitacicept in the Treatment of Refractory Rheumatoid Arthritis

Phase 2Difficult-to-treat Rheumatoid ArthritisRheumatoid Arthritis

Telitacicept 160mgStandard therapy

Peking University People's Hospital420 participants47 sites · ChinaCompletes Dec 2027

Compare CT.gov Full analysis →

Recruiting

A Clinical Study of CD19 CAR-T in Active Systemic Lupus Erythematosus

Phase 1Phase 2Systemic Lupus Erythematosus

CD19 CAR-T cell infusion

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology15 participants1 site · ChinaCompletes Dec 2025

Compare CT.gov Full analysis →

1–15 of 41

Explore/autoimmune immunology

Status

Phase

Pre-filtered to show active, later-stage trials with the strongest clinical signal.

41 results for “autoimmune immunology” · Recruiting · Phase 3 · Phase 2

Page 1 of 3

Recruiting

A Clinical Trial to Investigate 18F-AzaFol in the Diagnosis of Large Vessel Vasculitis

Phase 2Giant Cell Arteritis

AzaFolFDG

Insel Gruppe AG, University Hospital Bern70 participants1 site · SwitzerlandCompletes May 2029

Compare CT.gov Full analysis →

Recruiting

A Clinical Study of CD19 Universal CAR-γδT Cells in Active Systemic Lupus Erythematosus

Phase 1Phase 2Systemic Lupus Erythematosus

CD19 Universal CAR-γδ T Cells

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology15 participants1 site · ChinaCompletes Dec 2025

Compare CT.gov Full analysis →

Recruiting

Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty

Phase 2Rheumatic Disease

MethotrexateSulfasalazineHydroxychloroquine+24 more

NYU Langone Health80 participants1 site · United StatesCompletes Jan 2028

Compare CT.gov Full analysis →

Recruiting

Immunosuppression and COVID-19 Boosters

Phase 3COVID-19

diphtheria and tetanus toxoids (adsorbed) vaccineCOVID-19 vaccine

Kirby Institute320 participants5 sites · AustraliaCompletes Dec 2026

Compare CT.gov Full analysis →

Recruiting

Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia Areata

Phase 2Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (Apeced)Alopecia Areata

Ruxolitinib

National Institute of Allergy and Infectious Diseases (NIAID)70 participants1 site · United StatesCompletes Dec 2027

Compare CT.gov Full analysis →

Recruiting

Randomized Stepped Wedge Study of Emapalumab in APECED Enteritis

Phase 2Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy Enteritis

Emapalumab

National Institute of Allergy and Infectious Diseases (NIAID)30 participants1 site · United StatesCompletes Mar 2031

Compare CT.gov Full analysis →

Recruiting

A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)

Phase 3Systematic Lupus ErythematosusCutaneous Lupus Erythematosus

EnpatoranPlaceboStandard of care (SoC)

EMD Serono Research & Development Institute, Inc.202 participants57 sites · United States, Australia, BrazilCompletes May 2029

Compare CT.gov Full analysis →

Recruiting

MB-CART19.1 in Refractory SLE

Phase 1Phase 2SLE - Systemic Lupus Erythematosus

MB-CART19.1

Miltenyi Biomedicine GmbH29 participants3 sites · GermanyCompletes Sep 2027

Compare CT.gov Full analysis →

Recruiting

STep-up and Step-down Therapeutic Strategies in Childhood ARthritiS

Phase 3Oligoarthritis, JuvenilePolyarthritis, Juvenile, Rheumatoid Factor Negative

EtanerceptMethotrexateIntra-articular corticosteroid injections

Istituto Giannina Gaslini260 participants1 site · ItalyCompletes Feb 2025

Compare CT.gov Full analysis →

Recruiting

Efficacy and Safety of CAR-T Cells Therapy for Chronic or Refractory Primary Immune Thrombocytopenia (ITP)

Phase 1Phase 2ITP - Immune Thrombocytopenia

CAR-T cells

920th Hospital of Joint Logistics Support Force of People's Liberation Army of China10 participants1 site · ChinaCompletes Jan 2026

Compare CT.gov Full analysis →

Recruiting

Ublituximab in Autoantibody Positive Immune Mediated Necrotizing Myopathy

Phase 2Autoimmune Disorders

UblituximabPlacebo for Ublituximab

National Institute of Allergy and Infectious Diseases (NIAID)30 participants8 sites · United StatesCompletes Aug 2028

Compare CT.gov Full analysis →

Recruiting

VIBRANT: VIB4920 for Active Lupus Nephritis

Phase 2Lupus Nephritis

VIB4920Placebo for VIB4920

National Institute of Allergy and Infectious Diseases (NIAID)74 participants17 sites · United StatesCompletes Jun 2028

Compare CT.gov Full analysis →

Recruiting

Autologous Gene Therapy for Artemis-Deficient SCID

Phase 1Phase 2Severe Combined Immunodeficiency

AProArt-CD34CliniMACS® CD34 Reagent System cell sorter deviceBusulfan

University of California, San Francisco24 participants1 site · United StatesCompletes Jun 2038

Compare CT.gov Full analysis →

Recruiting

Efficacy and Safety of Telitacicept in the Treatment of Refractory Rheumatoid Arthritis

Phase 2Difficult-to-treat Rheumatoid ArthritisRheumatoid Arthritis

Telitacicept 160mgStandard therapy

Peking University People's Hospital420 participants47 sites · ChinaCompletes Dec 2027

Compare CT.gov Full analysis →

Recruiting

A Clinical Study of CD19 CAR-T in Active Systemic Lupus Erythematosus

Phase 1Phase 2Systemic Lupus Erythematosus

CD19 CAR-T cell infusion

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology15 participants1 site · ChinaCompletes Dec 2025

Compare CT.gov Full analysis →

1–15 of 41